Description
Interferon beta-1a, marketed under the brand name ReliBeta, It is an prescription medication that has been Approved 1986. Interferon alpha (IFN-α), a cytokine that is responsible for regulating and activating the immune response, was the first cancer immunotherapy.
What is ReliBeta (Interferon beta-1a) ?
Interferon beta-1a is used for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome (CIS), relapsing-remitting disease, and active secondary progressive disease, in adults.
How To Get Access ReliBeta (Interferon beta-1a) For Personal Use ?
To get access to ReliBeta (Interferon beta-1a), you need a prescription from a doctor, as it is a prescription-only medication. Your prescription will be filled through a specialty pharmacy, which will handle insurance and coordinate delivery of the medication to you. Your doctor will also need to provide specific information for the prescription to be filled correctly.
However, patients in India can legally access it through the provision called the Named Patient Program (NPP). ReliBeta (Interferon beta-1a) prices may fluctuate over time because of market dynamics and regulatory changes. It can be imported for personal use under “Named Patient Program” treatment in multiple countries, including the Singapore, Kuala Lumpur (Malaysia), Bangkok (Thailand), Jakarta, Surabaya, Bandung (Indonesia), Manila, Cebu (Philippines), Ho Chi Minh City, Hanoi (Vietnam), Yangon (Myanmar), Phnom Penh (Cambodia), Vientiane (Laos), UAE, Saudi Arabia, Argentina, Brazil, UK, Hungary, Ireland, Latvia, Slovakia, Czech Republic, Belgium, Lithuania, Greece, Spain, Zimbabwe, Australia, and New Zealand.
To order or inquire about ReliBeta (Interferon beta-1a) international access, you can contact Verve Biosciences – a trusted pharmaceutical exporter, supplier, and distributor of anti-cancer and specialty medications.
📧 Email: urgent@cancermedicinesnetwork.com
📞 Call or WhatsApp: 9910645395 or 9910645395
Note: Availability may vary by country and is subject to regulatory approvals.
